1. ¹Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland
2. ²Department of Pharmaceutical Chemistry, University of Kuopio, Kuopio, Finland
3. ³Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
4. ⁴Novamass Analytical Ltd, Kiviharjuntie, Oulu, Finland
5. ⁵Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine University of Düsseldorf, Universitatsstrasse 1, Düsseldorf, Germany

Correspondence: M Rahnasto, Department of Pharmacology and Toxicology, PO BOX 1627, 70211 Kuopio, Finland. E-mail: Minna.Rahnasto@uku.fi

Received 21 January 2007; Revised 9 July 2007; Accepted 30 July 2007; Published online 9 October 2007.

Abstract

The compulsive nature of tobacco use is attributable to nicotine addiction. Nicotine is eliminated by metabolism through the cytochrome P450 2A6 (CYP2A6) enzyme in liver. Inhibition of CYP2A6 by chemical compounds may represent a potential supplement to anti-smoking therapy. The purpose of this study was to rationally design potent inhibitors of CYP2A6. 3D-QSAR models were constructed to find out which structural characteristics are important for inhibition potency. Specifically located hydrophobic and hydrogen donor features were found to affect inhibition potency. These features were used in virtual screening of over 60 000 compounds in the Maybridge chemical database. A total of 22 candidate molecules were selected and tested for inhibition potency. Four of these were potent and selective CYP2A6 inhibitors with IC₅₀ values lower than 1 M. They represent novel structures of CYP2A6 inhibitors, especially N1-(4-fluorophenyl)cyclopropane-1-carboxamide. This compound can be used as a lead in the design of CYP2A6 inhibitor drugs to combat nicotine addiction.